ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
ORIC Pharmaceuticals, a clinical-stage oncology firm, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 5:35 p.m. GMT. The discussion will be available via a live webcast on the company’s investor website, with a replay accessible for 90 days post-event.
ORIC is focused on developing therapies to combat cancer resistance, with candidates including ORIC-533 for multiple myeloma, ORIC-114 targeting specific cancer mutations, and ORIC-944 for prostate cancer. For more information, visit www.oricpharma.com.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 5:35 p.m. GMT.
A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
When is ORIC Pharmaceuticals participating in the Jefferies London Healthcare Conference?
How can I watch the ORIC Pharmaceuticals fireside chat?
What are the key drug candidates of ORIC Pharmaceuticals?
What is the focus of ORIC Pharmaceuticals?
